Full Text
POSB403 Reimbursed Cost for Monoclonal Antibodies in Bulgaria: A Case with Adalimumab and Pembrolizumab

Abstract

Authors

M Kamusheva V Georgieva L Marinov E Boncheva G Petrova

Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×